常见MC1R功能丧失变异与帕金森病进展加速相关
该纵向队列研究基于PPMI及三项美国多中心临床试验的复制队列,评估MC1R功能丧失变异与帕金森病进展的关联。结果显示,在散发性帕金森病患者中,MC1R功能丧失携带者运动衰退速度较非携带者快30%,复制队列中快50%;小样本前驱期队列中,携带者转化为帕金森病的风险增加4倍以上。
要点
- MC1R功能丧失变异在欧洲裔帕金森病患者中携带率超过60%。
- 携带者运动衰退速度在发现队列快30%、复制队列快50%。
- 前驱期携带者转化为帕金森病的风险增加4倍以上。
核心结论
- MC1R功能丧失变异可能定义了一个大的、易于识别的遗传亚组,该亚组帕金森病进展加速,有助于预后分层和临床试验富集。
研究设计与样本
- 纵向队列研究,使用PPMI队列2010年7月至2026年1月数据及三项美国多中心随机临床试验(SURE-PD 2期、SURE-PD3、STEADY-PD III)2009年6月至2019年6月数据作为复制队列,随访长达12年。
- PPMI中926例有全基因组测序数据的帕金森病患者排除66例无多巴胺缺乏及51例已知帕金森病相关基因致病变异后,剩余809例按MC1R功能丧失携带状态分层(携带者505例,非携带者304例),并根据LRRK2和GBA携带状态分为散发性帕金森病(383例)和单基因帕金森病(426例)。
- 复制队列包括587例帕金森病患者(携带者410例,非携带者177例);另评估53例PPMI前驱期帕金森病参与者(携带者34例,非携带者19例)。
临床怎么用
- 对于欧洲裔帕金森病患者,检测MC1R功能丧失变异可能有助于识别进展更快的亚组,用于预后咨询和临床试验分层富集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Melanocortin 1 receptor (MC1R) is a key regulator of pigmentation and oxidative stress implicated in Parkinson disease (PD). MC1R loss-of-function variants, defined by experimentally demonstrated reductions in MC1R function, are carried by more than 60% of individuals of European descent. OBJECTIVE: To determine whether MC1R loss-of-function variants are associated with accelerated PD progression. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal cohort study used data from July 2010 to January 2026 in the Parkinson Progression Markers Initiative (PPMI) cohort and June 2009 to June 2019 in a replication cohort using 3 US-based multicenter randomized clinical trials (SURE-PD phase 2, SURE-PD3, and STEADY-PD III), with up to 12 years of follow-up. Analysis was performed in May 2026. Of 926 PPMI participants with PD and available genomewide sequencing data, 66 without dopamine deficiency and 51 with pathogenic variants in known PD-associated genes were excluded. The remaining 809 participants were stratified by MC1R loss-of-function carrier status (505 carriers and 304 noncarriers) and classified as having sporadic PD (n = 383) or monogenic PD (n = 426) based on LRRK2 and GBA carrier status. The replication cohort included 587 participants with PD (410 carriers and 177 noncarriers). An additional 53 PPMI participants with prodromal PD (34 carriers and 19 noncarriers) were assessed. EXPOSURES: MC1R loss-of-function carrier status. MAIN OUTCOMES AND MEASURES: Rate of motor decline per Movement Disorder Society Unified Parkinson's Disease Rating Scale Part III score, assessed via linear mixed-effects models adjusted for age at onset, sex, race, baseline score, and levodopa equivalent daily dose. Phenoconversion risk, assessed via Fine-Gray subdistribution hazards model. RESULTS: Among 383 participants with sporadic PD, 130 were female, 253 were male, and the mean (SD) age at onset was 61.3 (9.9) years for MC1R loss-of-function carriers and 64.6 (10.5) for noncarriers. MC1R loss-of-function carriers exhibited 30% faster motor decline (β, 0.57 points/year; 95% CI, 0.16-0.98; P = .006) than noncarriers. In the replication cohort, MC1R loss-of-function carriers exhibited 50% faster motor decline than noncarriers (β, 1.37; 95% CI, 0.28-2.46; P = .01). In a small prodromal cohort, MC1R loss-of-function carriers showed a more than 4-fold increased risk of phenoconversion to PD (subdistribution hazard ratio, 4.75; 95% CI, 1.48-15.27; P = .009). CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that MC1R loss-of-function variants may define a large, readily identifiable genetic subgroup with accelerated progression, highlighting their utility for potential prognostic stratification and clinical trial enrichment in patients of European descent with PD.
引用
- Schumacher JG, Zhang X, Wang J, et al. Common MC1R Variants and Parkinson Disease Progression. JAMA Neurol. 2026. PMID: 42709445. doi:10.1001/jamaneurol.2026.2998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。